N-(2-aminophenyl)-4-(3-cyanopyridin-2-yl)benzamide | 1027500-19-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-aminophenyl)-4-(3-cyanopyridin-2-yl)benzamide
• CAS: 1027500-19-1
• 化学式: C₁₉H₁₄N₄O
• 分子量: 314.346
• InChiKey: ZQPGFKNMOSRNOQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  91.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  n-(2-t-butoxycarbonylaminophenyl)-4-(3-cyanopyridin-2-yl)benzamide 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 20.0h， 以82%的产率得到N-(2-aminophenyl)-4-(3-cyanopyridin-2-yl)benzamide
  参考文献：
  名称：

  Benzamide Compounds

  摘要：

  这项发明涉及公式（I）的苯甲酰胺化合物，其中R1a、R1b、R1c、R2、R3、R4、m和n具有描述中定义的任意含义；它们的制备过程，含有它们的药物组合物以及它们在制造用作抗增殖剂的药物时的用途，用于预防或治疗对组蛋白去乙酰化酶（HDAC）抑制敏感的肿瘤或其他增殖性疾病。

  公开号：

  US20080293687A1

文献信息

• Benzamide compounds
  申请人：AstraZeneca

  公开号：US07897778B2

  公开（公告）日：2011-03-01

  The invention concerns benzamide compounds of Formula (I), wherein R1a, R1b, R1c, R2, R3, R4, m and n have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of histone deacetylase (HDAC).

  本发明涉及式(I)的苯甲酰胺化合物，其中R1a、R1b、R1c、R2、R3、R4、m和n具有描述中定义的任何含义；它们的制备方法，含有它们的制药组合物以及它们在制造用作组织蛋白去乙酰化酶（HDAC）抑制剂的药物的预防或治疗对肿瘤或其他增生性疾病敏感的增生症状中的使用。
• COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS
  申请人：Larsson Pia

  公开号：US20140051716A1

  公开（公告）日：2014-02-20

  There is provided a compound which is a histone deacetylase (HDAC) inhibitor, or a pharmaceutically acceptable ester, amide, solvate or salt thereof, for use in: (I) treating or preventing a pathological condition associated with excess fibrin deposition and/or thrombus formation; and/or (II) potentiating the degradation of fibrin deposits and preventing such deposits associated with pathological conditions or which may lead to such conditions, wherein the HDAC inhibitor, and the dose thereof, is as described in the description. There is also provided valproic acid, or a pharmaceutically acceptable salt thereof, for use in improving or normalizing endogenous fibrinolysis impaired by local or systemic inflammation.
• US7897778B2
  申请人：——

  公开号：US7897778B2

  公开（公告）日：2011-03-01
• [EN] BENZAMIDE COMPOUNDS<br/>[FR] COMPOSES DE BENZAMIDE
  申请人：ASTRAZENECA AB

  公开号：WO2006024841A2

  公开（公告）日：2006-03-09

  The invention concerns benzamide compounds of Formula (I), wherein R1a, R1b, R1c, R2, R3, R4, m and n have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of histone deacetylase (HDAC).